Skip to main content
SpringerLink
Log in

Vascular Effects of Inflammation and Oxidative Stress in CKD

  • Chapter
  • First Online:
Cardio-Renal Clinical Challenges

  • 1409 Accesses

Abstract

Chronic kidney disease (CKD) affects about 10 % of the general population [1] and, with disease progression, increasingly associates with excessive mortality risk, mainly due to cardiovascular complications [2]. Evidence suggests that CKD is associated with premature aging [3]. In end-stage renal disease (ESRD) patients on dialysis, the annual mortality rate, 10–20 % depending on the country/region, is comparable to that of patients with some common forms of metastatic cancer [4]. Even a slight decrease in glomerular filtration rate (GFR) predicts cardiovascular risk [5]. Although traditional (i.e., Framingham) risk factors, such as age, smoking, dyslipidemia, hypertension, and diabetes mellitus are common and predict cardiovascular mortality in CKD patients, especially in patients with mild to moderate CKD, so called novel risk factors, such as inflammation and oxidative stress, are also highly prevalent in these patients and are major driving forces for the uremic phenotype, which commonly includes both premature cardiovascular disease and protein-energy wasting (PEW) [6]. The risk factor profile is markedly different in the uremic milieu and chemical alterations of molecules in the uremic milieu may transform them and change their pro-atherogenic potential. This chapter focuses on the impact of inflammation and oxidative stress on cardiovascular complications in CKD population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Krol E, Rutkowski B, Czarniak P, Kraszewska E, Lizakowski S, Szubert R, et al. Early detection of chronic kidney disease: results of the PolNef study. Am J Nephrol. 2009;29(3):264–73.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–9.

    Article  CAS  PubMed  Google Scholar 

  3. Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis. 2013;62(2):339–51.

    Article  PubMed  Google Scholar 

  4. Carrero JJ, de Jager DJ, Verduijn M, Ravani P, De Meester J, Heaf JG, et al. Cardiovascular and noncardiovascular mortality among men and women starting dialysis. Clin J Am Soc Nephrol. 2011;6(7):1722–30.

    Article  PubMed  Google Scholar 

  5. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20(6):1048–56.

    Article  CAS  PubMed  Google Scholar 

  6. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3(2):505–21.

    Article  CAS  PubMed  Google Scholar 

  7. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5):1899–911.

    Article  CAS  PubMed  Google Scholar 

  8. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15(5):329–37.

    Article  PubMed  Google Scholar 

  9. Eustace JA, Astor B, Muntner PM, Ikizler TA, Coresh J. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int. 2004;65(3):1031–40.

    Article  CAS  PubMed  Google Scholar 

  10. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis. 2002;39(2):266–73.

    Article  CAS  PubMed  Google Scholar 

  11. Carrero JJ, Axelsson J, Avesani CM, Heimburger O, Lindholm B, Stenvinkel P. Being an inflamed peritoneal dialysis patient – a Dante’s journey. Contrib Nephrol. 2006;150:144–51.

    Article  PubMed  Google Scholar 

  12. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010;77(6):550–6.

    Article  CAS  PubMed  Google Scholar 

  13. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648–58.

    Article  CAS  PubMed  Google Scholar 

  14. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant. 1999;14(8):1956–60.

    Article  CAS  PubMed  Google Scholar 

  15. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1998;18(4):387–94.

    CAS  PubMed  Google Scholar 

  16. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol. 2003;14(7):1871–9.

    Article  CAS  PubMed  Google Scholar 

  17. Varagunam M, Finney H, Trevitt R, Sharples E, McCloskey DJ, Sinnott PJ, et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis. 2004;43(3):502–7.

    Article  CAS  PubMed  Google Scholar 

  18. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68(2):766–72.

    CAS  PubMed  Google Scholar 

  19. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol. 2004;38(5):405–16.

    Article  PubMed  Google Scholar 

  20. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease–what have we learned in 10 years? Semin Dial. 2010;23(5):498–509.

    Article  PubMed  Google Scholar 

  21. Grootendorst DC, de Jager DJ, Brandenburg VM, Boeschoten EW, Krediet RT, Dekker FW. Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients–no additional power for mortality prediction with high-sensitivity CRP. Nephrol Dial Transplant. 2007;22(11):3277–84.

    Article  CAS  PubMed  Google Scholar 

  22. Stenvinkel P, Wanner C, Metzger T, Heimburger O, Mallamaci F, Tripepi G, et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int. 2002;62(5):1791–8.

    Article  PubMed  Google Scholar 

  23. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia–the good, the bad, and the ugly. Kidney Int. 2005;67(4):1216–33.

    Article  CAS  PubMed  Google Scholar 

  24. Suliman ME, Heimburger O, Barany P, Anderstam B, Pecoits-Filho R, Rodriguez Ayala E, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003;14(6):1614–22.

    Article  CAS  PubMed  Google Scholar 

  25. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001;16(9):1863–9.

    Article  CAS  PubMed  Google Scholar 

  26. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.

    Article  CAS  PubMed  Google Scholar 

  27. Libby P, Nahrendorf M, Pittet MJ, Swirski FK. Diversity of denizens of the atherosclerotic plaque: not all monocytes are created equal. Circulation. 2008;117(25):3168–70.

    Article  PubMed  Google Scholar 

  28. Jialal I, Verma S, Devaraj S. Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clin Chem. 2009;55(2):206–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.

    Article  CAS  PubMed  Google Scholar 

  30. Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif. 2005;23(1):72–8.

    Article  CAS  PubMed  Google Scholar 

  31. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE−/− mice. Atherosclerosis. 2008;196(1):248–55.

    Article  CAS  PubMed  Google Scholar 

  32. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005;102(23):8309–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Clapp BR, Hirschfield GM, Storry C, Gallimore JR, Stidwill RP, Singer M, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation. 2005;111(12):1530–6.

    Article  PubMed  Google Scholar 

  34. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302(1):37–48.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897–908.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang L, Kao WH, Berthier-Schaad Y, Plantinga L, Fink N, Smith MW, et al. C-Reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. Am J Kidney Dis. 2007;49(1):118–26.

    Article  CAS  PubMed  Google Scholar 

  37. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23(7):1258–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767–72.

    Article  CAS  PubMed  Google Scholar 

  39. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002;17(9):1684–8.

    Article  CAS  PubMed  Google Scholar 

  40. Pachaly MA, do Nascimento MM, Suliman ME, Hayashi SY, Riella MC, Manfro RC, et al. Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. Blood Purif. 2008;26(2):204–10.

    Article  CAS  PubMed  Google Scholar 

  41. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148(2):209–14.

    Article  CAS  PubMed  Google Scholar 

  42. Netea MG, Selzman CH, Kullberg BJ, Galama JM, Weinberg A, Stalenhoef AF, et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol. 2000;30(2):541–9.

    Article  CAS  PubMed  Google Scholar 

  43. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis. 2002;39(2):274–82.

    Article  CAS  PubMed  Google Scholar 

  44. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6–174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22(24):2243–52.

    Article  CAS  PubMed  Google Scholar 

  45. Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol. 2006;17(3):863–70.

    Article  CAS  PubMed  Google Scholar 

  46. Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P. The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens. 2010;19(1):37–42.

    Article  CAS  PubMed  Google Scholar 

  47. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimburger O, Barany P, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007;2(5):889–97.

    Article  CAS  PubMed  Google Scholar 

  48. Suliman ME, Qureshi AR, Carrero JJ, Barany P, Yilmaz MI, Snaedal-Jonsdottir S, et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM. 2008;101(5):397–405.

    Article  CAS  PubMed  Google Scholar 

  49. Witasp A, Ryden M, Carrero JJ, Qureshi AR, Nordfors L, Naslund E, et al. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One. 2013;8(5):e63493.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol. 2011;6(4):785–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, Heimburger O, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(1):110–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(11):1716–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Doller D, Katholnig K, et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol. 2012;23(5):934–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Wetmore JB, Lovett DH, Hung AM, Cook-Wiens G, Mahnken JD, Sen S, et al. Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton). 2008;13(7):593–600.

    Article  CAS  Google Scholar 

  55. Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial. 2009;22(4):357–62.

    Article  PubMed  Google Scholar 

  56. Kuro-o M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol. 2013;9(11):650–60.

    Article  CAS  PubMed  Google Scholar 

  57. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62(5):1524–38.

    Article  CAS  PubMed  Google Scholar 

  58. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65(3):1009–16.

    Article  PubMed  Google Scholar 

  59. Chmielewski M, Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol. 2008;21(5):635–44.

    CAS  PubMed  Google Scholar 

  60. Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in chronic kidney disease. Semin Dial. 2009;22(4):405–8.

    Article  PubMed  Google Scholar 

  61. Himmelfarb J, McMenamin E, McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int. 2002;61(2):705–16.

    Article  CAS  PubMed  Google Scholar 

  62. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Krankel N, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013;38(4):754–68.

    Article  CAS  PubMed  Google Scholar 

  63. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999;56(3):1078–83.

    Article  CAS  PubMed  Google Scholar 

  64. Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int. 1998;53(6):1748–54.

    Article  CAS  PubMed  Google Scholar 

  65. Shainkin-Kestenbaum R, Caruso C, Berlyne GM. Reduced superoxide dismutase activity in erythrocytes of dialysis patients: a possible factor in the etiology of uremic anemia. Nephron. 1990;55(3):251–3.

    Article  CAS  PubMed  Google Scholar 

  66. Grahl DA, Axelsson J, Nordfors L, Heimburger O, Barany P, Qureshi AR, et al. Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients. Blood Purif. 2007;25(2):210–8.

    Article  CAS  PubMed  Google Scholar 

  67. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl. 2003;84:S172–6.

    Article  CAS  PubMed  Google Scholar 

  68. Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol. 2010;73(6):431–8.

    Article  CAS  PubMed  Google Scholar 

  69. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA. IL-1beta receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol. 2011;22(3):437–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  70. Gonzalez-Espinoza L, Rojas-Campos E, Medina-Perez M, Pena-Quintero P, Gomez-Navarro B, Cueto-Manzano AM. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transplant. 2012;27(5):2023–8.

    Article  CAS  PubMed  Google Scholar 

  71. Biolo G, Ciocchi B, Bosutti A, Situlin R, Toigo G, Guarnieri G. Pentoxifylline acutely reduces protein catabolism in chronically uremic patients. Am J Kidney Dis. 2002;40(6):1162–72.

    Article  CAS  PubMed  Google Scholar 

  72. Duchatelle V, Kritikou EA, Tardif JC. Clinical value of drugs targeting inflammation for the management of coronary artery disease. Can J Cardiol. 2012;28(6):678–86.

    Article  PubMed  Google Scholar 

  73. van der Valk FM, van Wijk DF, Stroes ES. Novel anti-inflammatory strategies in atherosclerosis. Curr Opin Lipidol. 2012;23(6):532–9.

    Article  PubMed  Google Scholar 

  74. Ramos LF, Kane J, McMonagle E, Le P, Wu P, Shintani A, et al. Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. J Ren Nutr. 2011;21(3):211–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  75. Himmelfarb J, Ikizler TA, Ellis C, Wu P, Shintani A, Dalal S, et al. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial. J Am Soc Nephrol. 2014;25(3):623–33.

    Article  CAS  PubMed  Google Scholar 

  76. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr. 2007;17(5):296–304.

    Article  PubMed  Google Scholar 

  77. Nascimento MM, Suliman ME, Silva M, Chinaglia T, Marchioro J, Hayashi SY, et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int. 2010;30(3):336–42.

    Article  CAS  PubMed  Google Scholar 

  78. Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, Meyer CJ, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011;33(5):469–76.

    Article  CAS  PubMed  Google Scholar 

  79. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365(4):327–36.

    Article  CAS  PubMed  Google Scholar 

  80. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369(26):2492–503.

    Article  PubMed  Google Scholar 

  81. Himmelfarb J, Tuttle KR. New therapies for diabetic kidney disease. N Engl J Med. 2013;369(26):2549–50.

    Article  CAS  PubMed  Google Scholar 

  82. Cardozo LF, Pedruzzi LM, Stenvinkel P, Stockler-Pinto MB, Daleprane JB, Leite Jr M, et al. Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2. Biochimie. 2013;95(8):1525–33.

    Article  CAS  PubMed  Google Scholar 

  83. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266–73.

    Article  CAS  PubMed  Google Scholar 

  84. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  85. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–407.

    Article  CAS  PubMed  Google Scholar 

  86. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.

    Article  CAS  PubMed  Google Scholar 

  87. Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of vitamin D in atherosclerosis. Circulation. 2013;128(23):2517–31.

    Article  PubMed  Google Scholar 

  88. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010;21(2):353–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. Chitalia N, Ismail T, Tooth L, Boa F, Hampson G, Goldsmith D, et al. Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS One. 2014;9(3):e91363.

    Article  PubMed Central  PubMed  Google Scholar 

  90. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5(5):905–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  91. Donate-Correa J, Dominguez-Pimentel V, Mendez-Perez ML, Muros-de-Fuentes M, Mora-Fernandez C, Martin-Nunez E, et al. Selective vitamin d receptor activation as anti-inflammatory target in chronic kidney disease. Mediators Inflamm. 2014;2014:670475.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  92. Stinghen AE, Goncalves SM, Bucharles S, Branco FS, Gruber B, Hauser AB, et al. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif. 2010;29(4):352–6.

    Article  CAS  PubMed  Google Scholar 

  93. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008;3(1):61–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  94. Ikizler TA, Cano NJ, Franch H, Fouque D, Himmelfarb J, Kalantar-Zadeh K, et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int. 2013;84(6):1096–107.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, ul. Debinki 7, Gdansk, 80-211, Poland

    Michal Chmielewski MD, PhD

  2. Baxter Novum and Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, K56 Karolinska University Hospital Huddinge, Stockholm, 14186, Sweden

    Bengt Lindholm MD, PhD

  3. Department of Renal Medicine, Karolinska University Hospital Huddinge, Stockholm, 19273, Sweden

    Peter Stenvinkel MD, PhD

Authors
  1. Michal Chmielewski MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bengt Lindholm MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Stenvinkel MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michal Chmielewski MD, PhD .

Editor information

Editors and Affiliations

  1. Renal and Transplantation Department, Guy's Hospital, London, United Kingdom

    David Goldsmith

  2. Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania

    Adrian Covic

  3. Karolinska Institutet Danderyd University Hospital, Stockholm, Sweden

    Jonas Spaak

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Chmielewski, M., Lindholm, B., Stenvinkel, P. (2015). Vascular Effects of Inflammation and Oxidative Stress in CKD. In: Goldsmith, D., Covic, A., Spaak, J. (eds) Cardio-Renal Clinical Challenges. Springer, Cham. https://doi.org/10.1007/978-3-319-09162-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-09162-4_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-09161-7

  • Online ISBN: 978-3-319-09162-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation